Your browser doesn't support javascript.
loading
Safety and immunogenicity of an HIV-1 gp120-CD4 chimeric subunit vaccine in a phase 1a randomized controlled trial.
Chua, Joel V; Davis, Charles; Husson, Jennifer S; Nelson, Amy; Prado, Ilia; Flinko, Robin; Lam, Ka Wing J; Mutumbi, Lydiah; Mayer, Bryan T; Dong, Dan; Fulp, William; Mahoney, Celia; Gerber, Monica; Gottardo, Raphael; Gilliam, Bruce L; Greene, Kelli; Gao, Hongmei; Yates, Nicole; Ferrari, Guido; Tomaras, Georgia; Montefiori, David; Schwartz, Jennifer A; Fouts, Timothy; DeVico, Anthony L; Lewis, George K; Gallo, Robert C; Sajadi, Mohammad M.
Afiliação
  • Chua JV; Division of Clinical Care and Research, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, USA.
  • Davis C; Division of Clinical Care and Research, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, USA.
  • Husson JS; Division of Clinical Care and Research, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, USA.
  • Nelson A; Division of Clinical Care and Research, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, USA.
  • Prado I; Division of Vaccine Research, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, USA.
  • Flinko R; Division of Vaccine Research, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, USA.
  • Lam KWJ; Division of Clinical Care and Research, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, USA.
  • Mutumbi L; Division of Clinical Care and Research, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, USA.
  • Mayer BT; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
  • Dong D; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
  • Fulp W; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
  • Mahoney C; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
  • Gerber M; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
  • Gottardo R; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA; Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
  • Gilliam BL; Division of Clinical Care and Research, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, USA.
  • Greene K; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA.
  • Gao H; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA.
  • Yates N; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA.
  • Ferrari G; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA.
  • Tomaras G; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA.
  • Montefiori D; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA.
  • Schwartz JA; Intralytix, Columbia, MD, USA.
  • Fouts T; Advanced BioScience Laboratories, Rockville, MD, USA.
  • DeVico AL; Division of Vaccine Research, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, USA; Global Virus Network, Baltimore, MD, USA.
  • Lewis GK; Division of Vaccine Research, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, USA; Global Virus Network, Baltimore, MD, USA.
  • Gallo RC; Global Virus Network, Baltimore, MD, USA; Division of Basic Science, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, USA.
  • Sajadi MM; Division of Clinical Care and Research, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, USA; Intralytix, Columbia, MD, USA. Electronic address: msajadi@ihv.umaryland.edu.
Vaccine ; 39(29): 3879-3891, 2021 06 29.
Article em En | MEDLINE | ID: mdl-34099328
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Infecções por HIV / Vacinas contra a AIDS / Imunogenicidade da Vacina Tipo de estudo: Clinical_trials Limite: Adult / Animals / Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Infecções por HIV / Vacinas contra a AIDS / Imunogenicidade da Vacina Tipo de estudo: Clinical_trials Limite: Adult / Animals / Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article